Trial Profile
Efficacy, safety and tolerability of XBD173 in patients with generalized anxiety disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 May 2010
Price :
$35
*
At a glance
- Drugs XBD 173 (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Nov 2007 Status changed from in progress to completed
- 30 Jan 2006 New trial record.